Literature DB >> 30195816

Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: A phase I-II study.

Céline Gregoire1, Alexandra Briquet2, Caroline Pirenne3, Chantal Lechanteur2, Edouard Louis3, Yves Beguin4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30195816     DOI： 10.1016/j.dld.2018.08.015

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


× No keyword cloud information.
  8 in total

1.  Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe3O4@Al(OH)3 nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution.

Authors:  Sarah Belderbos; Manuel Antonio González-Gómez; Frederik Cleeren; Jens Wouters; Yolanda Piñeiro; Christophe M Deroose; An Coosemans; Willy Gsell; Guy Bormans; Jose Rivas; Uwe Himmelreich
Journal:  EJNMMI Res       Date:  2020-06-30       Impact factor: 3.138

Review 2.  Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review.

Authors:  Jeffrey Zheng-Hsien Ko; Sheeva Johnson; Maneesh Dave
Journal:  Biomolecules       Date:  2021-01-11

Review 3.  Research progress of the application of mesenchymal stem cells in chronic inflammatory systemic diseases.

Authors:  Fangfang Huang; Erick Thokerunga; Fajian He; Xinyu Zhu; Zi Wang; Jiancheng Tu
Journal:  Stem Cell Res Ther       Date:  2022-01-08       Impact factor: 6.832

4.  Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells.

Authors:  Jialing Liu; Xingqiang Lai; Yingying Bao; Wenfeng Xie; Zhishan Li; Jieying Chen; Gang Li; Tao Wang; Weijun Huang; Yuanchen Ma; Jiahao Shi; Erming Zhao; Andy Peng Xiang; Qiuli Liu; Xiaoyong Chen
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

Review 5.  Mesenchymal (Stem) Stromal Cells Based as New Therapeutic Alternative in Inflammatory Bowel Disease: Basic Mechanisms, Experimental and Clinical Evidence, and Challenges.

Authors:  Noemi Eiro; Maria Fraile; Alberto González-Jubete; Luis O González; Francisco J Vizoso
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

6.  ADSCs stimulated by VEGF-C alleviate intestinal inflammation via dual mechanisms of enhancing lymphatic drainage by a VEGF-C/VEGFR-3-dependent mechanism and inhibiting the NF-κB pathway by the secretome.

Authors:  Lei Zhang; Chen Ye; Peng Li; Chuanding Li; Weigang Shu; Yujie Zhao; Xiaolei Wang
Journal:  Stem Cell Res Ther       Date:  2022-09-05       Impact factor: 8.079

7.  MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process.

Authors:  Chantal Lechanteur; Alexandra Briquet; Virginie Bettonville; Etienne Baudoux; Yves Beguin
Journal:  Cells       Date:  2021-05-26       Impact factor: 6.600

Review 8.  Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress.

Authors:  Xiaomo Wu; Ju Jiang; Zhongkai Gu; Jinyan Zhang; Yang Chen; Xiaolong Liu
Journal:  Stem Cell Res Ther       Date:  2020-08-08       Impact factor: 6.832
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.